Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
The copper efflux transporters ATP7A and ATP7B sequester intracellular copper into the vesicular secretory pathway for export from the cell. The influence of these transporters on the pharmacodynamics of cisplatin, carboplatin, and oxaliplatin was investigated using human Menkes' disease fibroblasts (Me32a) that do not express either transporter and sublines molecularly engineered to express either ATP7A (MeMNK) or ATP7B (MeWND). Cellular copper levels were significantly higher in the Me32a cells than in the MeMNK and MeWND sublines. These transporter-proficient sublines were resistant to the cytotoxic effect of copper, cisplatin, and carboplatin but were hypersensitive to oxaliplatin. Whole-cell accumulation of platinum after a 24-h exposure was significantly increased in the MeMNK and MeWND cells for all three platinum drugs, but this was accompanied by an increase in the amount of platinum reaching the DNA only for oxaliplatin. Vesicles isolated from MeMNK cells contained more platinum after exposure to cisplatin and carboplatin, whereas the platinum content of vesicles from MeWND cells was increased after exposure to all three drugs. Although copper triggered relocalization of ATP7A from the perinuclear region to more peripheral locations, the platinum drugs did not. These results demonstrate that both ATP7A and ATP7B modulate the pharmacodynamics of all three clinically used platinum drugs. The data are consistent with the hypothesis that these copper exporters sequester the platinum drugs into subcellular compartments, limiting their cytotoxicity, similar to their effect on copper. However, in this model system, although copper is readily exported after vesicular sequestration, the platinum drugs are not.
Samimi
Goli
G
Department of Medicine, the Rebecca and John Moores University of California San Diego Cancer Center, Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, USA.
Katano
Kuniyuki
K
Holzer
Alison K
AK
Safaei
Roohangiz
R
Howell
Stephen B
SB
D000251:Adenosine Triphosphatases / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016190:Carboplatin / Q000494:pharmacology; D027682:Cation Transport Proteins / Q000378:metabolism*; D002455:Cell Division; D002945:Cisplatin / Q000494:pharmacology*; D003300:Copper / Q000378:metabolism / Q000494:pharmacology; D000073840:Copper-Transporting ATPases; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008853:Microscopy; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin; D010984:Platinum / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000378:metabolism*; D014162:Transfection
D000970:Antineoplastic Agents; D027682:Cation Transport Proteins; D009944:Organoplatinum Compounds; D011993:Recombinant Fusion Proteins; D000077150:Oxaliplatin; D010984:Platinum; D003300:Copper; D004247:DNA; D016190:Carboplatin; D000251:Adenosine Triphosphatases; C081184:ATP7A protein, human; C000612464:ATP7B protein, human; D000073840:Copper-Transporting ATPases; D002945:Cisplatin